Trial Profile

A Phase III Study to Assess the Safety, Tolerability, and Efficacy of MK0822 (Odanacatib) in Reducing the Risk of Bone Metastasis in Women With Breast Cancer.

Status: Withdrawn prior to enrolment

Phase of Trial: Phase III

Latest Information Update: 09 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Odanacatib (Primary)
Indications Bone metastases; Breast cancer
Focus Registrational; Therapeutic Use
Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

08 May 2019 This trial has been completed in Slovakia, according to European Clinical Trials Database.
02 May 2019 This trial has been discontinued in spain according to European Clinical Trials Database record.
11 Aug 2016 Planned End Date changed from 1 Aug 2008 to 1 Sep 2008.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com